Exosome Treatment Enhances Anti-Inflammatory M2 Macrophages and Reduces Inflammation-Induced Pyroptosis in Doxorubicin-Induced Cardiomyopathy

Dinender K. Singla *, Taylor A. Johnson and Zahra Tavakoli Dargani

Division of Metabolic and Cardiovascular Sciences, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA; tajohnson@knights.ucf.edu (T.A.J.); zahra.tavakoli@knights.ucf.edu (Z.T.D.)

* Correspondence: dinender.singla@ucf.edu; Tel.: +1-407-823-0953

Received: 12 August 2019; Accepted: 26 September 2019; Published: 9 October 2019

Abstract: Doxorubicin (Dox) is an effective antineoplastic agent used to treat cancers, but its use is limited as Dox induces adverse cardiotoxic effects. Dox-induced cardiotoxicity (DIC) can lead to heart failure and death. There is no study that investigates whether embryonic stem cell-derived exosomes (ES-Exos) in DIC can attenuate inflammation-induced pyroptosis, pro-inflammatory M1 macrophages, inflammatory cell signaling, and adverse cardiac remodeling. For this purpose, we transplanted ES-Exos and compared with ES-cells (ESCs) to examine pyroptosis, inflammation, cell signaling, adverse cardiac remodeling, and their influence on DIC induced cardiac dysfunction. Therefore, we used C57BL/6J mice ages 10 ± 2 weeks and divided them into four groups (n = 6–8/group): Control, Dox, Dox + ESCs, and Dox + ES-Exos. Our data shows that the Dox treatment significantly increased expression of inflammasome markers (TLR4 and NLRP3), pyroptotic markers (caspase-1, IL1-β, and IL-18), cell signaling proteins (MyD88, p-P38, and p-JNK), pro-inflammatory M1 macrophages, and TNF-α cytokine. This increased pyroptosis, inflammation, and cell signaling proteins were inhibited with ES-Exos or ESCs. Moreover, ES-Exos or ESCs increased M2 macrophages and anti-inflammatory cytokine, IL-10. Additionally, ES-Exos or ESCs treatment inhibited significantly cytoplasmic vacuolization, myofibril loss, hypertrophy, and improved heart function. In conclusion, for the first time we demonstrated that Dox-induced pyroptosis and cardiac remodeling are ameliorated by ES-Exos or ESCs.

Keywords: doxorubicin; cardiotoxicity; pyroptosis; inflammation; embryonic stem cells; exosomes

1. Introduction

Doxorubicin (Dox) is a secondary metabolite of Streptomyces peucetius var. caesius, a family of anthracyclines. This powerful drug is an antineoplastic therapeutic agent used to treat a wide variety of solid organ tumors and hematologic malignancies, including leukemia, lymphoma, breast cancer, and lung cancer in adults and pediatric patients [1–3]. However, medicinal use of this drug is limited due to acute and chronic side effects such as alopecia, vomiting, nausea, cardiac dysfunction, and heart failure [4,5]. Dox-induced cardiotoxicity (DIC) depends on the drug dose; however, it leads to complex and time-dependent cardiomyopathy that develops cardiac pathophysiological and cellular changes. Cardiomyocyte apoptosis, fibrosis, hypertrophy, and cellular vacuolization are reported by various investigators [6–8]. Apoptosis has also been reported in non-cardiac myocytes such as endothelial cells [9,10]. Recent studies suggest that DIC may involve infiltration of M1 macrophages that induces inflammation and pathogenesis [1,11]. However, this remains unknown whether presence of inflammation induces inflammation-mediated cell death—termed pyroptosis in DIC.
So far, oxidative stress has been considered as a major prognostic factor in DIC progression. Therefore, antioxidant therapeutic options were adapted to block these adverse cardiac events in response to Dox-induced cell death, remodeling, and decrease in cardiac function [6,12–18] with limited success. However, alternative strategies are still needed to impede these detrimental effects to the heart following Dox treatment.

Stem cells, particularly embryonic stem cells (ESCs), have been widely accepted as an effective therapeutic approach in many diseases, including cardiovascular disorders [8,19]. Albeit promising reports of success, these undifferentiated pluripotent cells have few fundamental issues such as the formation of teratomas, which is considered the major obstacle blocking ESCs from being considered for human use [20,21]. Moreover, following transplantation of ESCs, only a limited number of cells can engraft and differentiate into heart cells or participate in the inhibition of adverse cardiac remodeling [22,23]. Therefore, recent studies have focused on embryonic stem cell-derived exosomes (ES-Exos) as a safer alternative approach to ESC therapy [23–25]. Exosomes (Exos) are cell-derived vesicles, which contain proteins, lipids, growth factors, miRNAs, and anti-inflammatory cytokines that are released through exocytosis [1,26,27]. Recent literature suggests that ES-Exos have the potential to repair infarcted heart [28]. However, this remains to be established in the Dox-induced cardiotoxicity.

To the best of our knowledge, we report for the first time the following major findings of this study: 1) DIC promotes an inflammasome formation (TLR4 and NLRP3 proteins) that leads to inflammation-induced novel form of cell death, pyroptosis (caspase-1, IL1-β, and IL-18), 2) ES-Exos inhibit pyroptosis in a similar potential and capability as observed with ESCs, 3) Exos treatment convert pro-inflammatory M1 macrophages into anti-inflammatory M2 macrophages that attenuates pyroptosis in DIC, and 4) ES-Exos inhibit adverse cardiac remodeling and improve cardiac function.

2. Materials and Methods

2.1. Cell Culture and Exosomes Preparation

ES cells (CGR8, a mouse ES cell line) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured as previously described [1,29]. In brief, ESCs were cultured in 100 mm$^2$ tissue culture dishes (ThermoFisher Scientific Waltham, MA, USA) and grown with Dulbecco’s modified Eagle’s medium (DMEM; ThermoFisher Scientific; cat# 11965092) supplemented with 15% ES fetal bovine serum (Gibco; cat# 16141079, Gaithersburg, MD, USA), leukemia inhibitory factor (Millipore Sigma; cat# ESG1107, Burlington, MA, USA), glutamine (ThermoFisher Scientific; cat# 25030081), penicillin/streptomycin (P/S; ThermoFisher Scientific; cat# 15070063), sodium pyruvate (ThermoFisher Scientific; cat# 11360070), and β-mercaptoethanol (ThermoFisher Scientific; cat# 21985023). After 48 h, cell culture medium was replaced with serum-free knockout DMEM (ThermoFisher Scientific; cat# 10829018) supplemented with P/S. 48 h post-media exchange, exosomes were isolated using the Exoquick TC exosome isolation kit (SBI; cat# EXOTC50A-1, Palo Alto, CA, USA) according to the manufacturer’s instructions. In brief, the medium was collected from cell culture plates and centrifuged at 15000 rpm for 15 min to remove cell debris, and then the supernatant was transferred to a sterile tube. The collected supernatant was mixed with Exoquick-TC exosome precipitation solution (SBI) in a 5:1 ratio for 12 h at 4 °C according to the manufacturer’s protocol. Following this, the mixture was centrifuged at 15000× g for 1 h, and after aspirating the supernatant, the exosome pellet was obtained and stored at –80 °C for further use. Exos characterization using exosome specific markers HSP-70 and CD63 is recently reported by us [1].

2.2. Animal Preparation

All animal protocols were approved by University of Central Florida Institutional Animal Care and Use Committee (IACUC). C57BL/6j mice (10 ± 2 weeks of age, male and female; JAX: 000664) were assigned into four groups: Control (injected with normal saline), Dox, Dox + ESCs, and Dox + ES-Exos. There were $n = 6–8$ animals in each group.
Dox was injected in three intraperitoneal (i.p) injections (4 mg/kg body weight), on alternative days in a week time span (Monday, Wednesday, and Friday) for a cumulative dose of 12 mg/kg (Figure 1A). For treatment groups, ESCs (5 x 10^5 ESCs in 400 µL medium/injection) or ES-Exos (400 µL/injection with 50 µg concentration of ES-Exos) were injected on alternative days between Dox treatments (Tuesday, Thursday, and Saturday; Figure 1A). Body weight (BW) was measured before starting injections as well as at the time of sacrifice. Two weeks following the last injection, mice were sacrificed under sedation with 4% isoflurane via nose cone and subsequent cervical dislocation. Hearts were harvested, washed in phosphate buffered saline (PBS), weighed, and divided into two halves. The top portion was saved in RNA later for western blot analysis and RNA isolation, and the bottom portion was placed in 4% paraformaldehyde (Fisher Scientific) for immunohistochemistry staining.

2.3. Immunohistochemistry (IHC) Staining

The bottom half of the heart tissue preserved in paraformaldehyde was embedded in paraffin and serial sectioned at 5 µm thickness. Sections were placed on microscope slides and double immunohistochemistry (IHC) staining was performed, as previously described [6]. In brief, sections were deparaffinized, rehydrated, and then blocked with 10% normal goat serum blocking reagent (Vector Lab; cat# S-1000, Burlingame, CA, USA) for one hour at room temperature (RT) prior to incubation with primary antibodies for inflammasome markers; TLR4 (1:50; Abcam; cat# ab13556, Cambridge, MA, USA) and NLRP3 (1:50; Abcam; cat# ab214185), for pyroptotic markers; caspase-1 (1:50; Abcam; cat# ab138483), IL-1β (1:50; Abcam; cat# ab9722), and IL-18 (1:50; Abcam; cat# ab71495), for pro-inflammatory cytokine, TNF-α (1:50; Abcam; cat# 6671), for marker of M1 macrophages, induced nitric oxide synthase (iNOS; 1:50; Abcam; cat# 15323), for M2 macrophages marker, CD206 (1:50; Abcam; cat# 4693) and for anti-inflammatory cytokine, IL-10 (1:50; Abcam; cat# ab33471)
overnight at 4 °C. Following primary incubation, sections were incubated with a secondary antibody, Alexa 568 goat anti-rabbit (1:50; Invitrogen; cat# A-11011, Carlsbad, CA, USA) or Alexa 594 goat anti-rat (1:50; Invitrogen; cat# A-11007). Anti-α-sarcomeric actin antibody (1:30 dilution; Sigma-Aldrich; cat# 2172, Burlington, MA, USA), which specifically stains for cardiomyocytes, was applied on the sections. Following incubation with biotinylated Anti-Mouse IgG reagent (MOM kit, Vector Lab; cat# FMK-2201) and fluorescein Avidin DCS (green color reaction), slides were covered with mounting medium containing DAPI (4′,6-diamino-2-phenylindole; Vector Lab; Burlingame, CA; cat# NC9524612) and cover slipped. Pictures were taken using Olympus fluorescent (Center Valley, PA, USA) and Leica confocal (Buffalo Grove, IL, USA) microscopes. Quantitative data for pyroptotic cell death, secreted pro-inflammatory cytokine (TNF-α), anti-inflammatory cytokine (IL-10), and macrophages were calculated by dividing total positive cells over total DAPI times 100 ((total cells+/−/total DAPI)*100).

Graphs were created using image J and Sigma Plot software.

2.4. SDS-PAGE and Western Blot Analysis

Western blot was performed as previously reported [30]. In brief, the top portion of heart tissue saved in RNA later solution was lysed using the RIPA (radio-immunoprecipitation assay) lysis buffer, the supernatant was collected, and protein concentration was estimated via a Bio-Rad assay. 50 µg of protein was loaded into 10% or 12% sodium dodecyl sulfate (SDS) gels and run at 150 V for 1 h. Gels were transferred onto polyvinylidene difluoride (PVDF; BioRad; cat# 162-0177, Hercules, CA, USA) membranes (Bio-Rad, CA) using a semi-dry transfer machine (Bio-Rad). Membranes were blocked with 5% skim milk prior to incubation with primary antibodies for TLR4 (1:1000; Abcam; cat# ab13556), NLRP3 (1:1000; Cell Signaling; cat# D4D8T, Danvers, MA, USA), caspase-1 (1:1000; Abcam; cat# ab138483), IL-1β (1:1000; Abcam; cat# ab9722), IL-18 (1:1000; Abcam; cat# ab71495), TNF-α (1:500; Abcam; cat# ab6671), IL-10 (1:500; Abcam; cat# ab33471), MyD88 (1:1000; Abcam; cat# ab135693), p-P38 (1:1000; Cell Signaling; cat# 4631S), p-JNK (1:1000; Cell Signaling; cat# 4668S), MMP-9 (1:1000; Abcam; cat# ab38898), and β-actin (1:1000; Cell Signaling; cat# 4967L) overnight at 4 °C or one hour at RT. Following washing the membranes with 1XTBS-T buffer, goat anti-rabbit IgG-HRP (1:1000; Cell Signaling; cat# 7074S) or goat anti-rat IgG-HRP (1:1000; Santa Cruz Biotechnology; cat# sc-2006, Dallas, Texas, USA) secondary antibody was used for one hour at RT. After exposure with enhanced chemiluminescence (ECL) substrates (Fisher Scientific; cat# 32106), membranes were developed on x-ray film. Using captured images, densitometry analysis was performed using image J.

2.5. cDNA Synthesis and RT-PCR Reaction

Total RNA from heart tissue was isolated by using a Trizol™ reagent. One µg of RNA was reverse-transcribed into cDNA using the Superscript™ III First Strand Synthesis system (Invitrogen, Carlsbad, CA). CDNA (50 ng) sample prior to incubation with primary antibodies for TLR4 (1:1000; Abcam; cat# ab13556), NLRP3 (1:1000; Cell Signaling; cat# D4D8T, Danvers, MA, USA), caspase-1 (1:1000; Abcam; cat# ab138483), IL-1β (1:1000; Abcam; cat# ab9722), IL-18 (1:1000; Abcam; cat# ab71495), TNF-α (1:500; Abcam; cat# ab6671), IL-10 (1:500; Abcam; cat# ab33471), MyD88 (1:1000; Abcam; cat# ab135693), p-P38 (1:1000; Cell Signaling; cat# 4631S), p-JNK (1:1000; Cell Signaling; cat# 4668S), MMP-9 (1:1000; Abcam; cat# ab38898), and β-actin (1:1000; Cell Signaling; cat# 4967L) overnight at 4 °C or one hour at RT. Following washing the membranes with 1XTBS-T buffer, goat anti-rabbit IgG-HRP (1:1000; Cell Signaling; cat# 7074S) or goat anti-rat IgG-HRP (1:1000; Santa Cruz Biotechnology; cat# sc-2006, Dallas, Texas, USA) secondary antibody was used for one hour at RT. After exposure with enhanced chemiluminescence (ECL) substrates (Fisher Scientific; cat# 32106), membranes were developed on x-ray film. Using captured images, densitometry analysis was performed using image J.

Table 1. Primer sequences used for the study.

| Target     | Forward Primer | Reverse Primer |
|------------|----------------|----------------|
| GAPDH      | 5′-ACCCAGAAGACTGTGGATGG-3′ | 5′-CACATGGGGTAGAAGAC-3′ |
| Caspase-1  | 5′-GAAGGCACATGGCTAGAGG-3′ | 5′-CTGCCTGTGTCATAGCAG-3′ |
| IL-1β      | 5′-AACCTGCTGTGGATGGACT-3′ | 5′-CAGCGAGCGCTTTTGTG-3′ |
| IL-18      | 5′-ACTTGCCGACTTCACGT-3′ | 5′-GTCCTGTCTGGGTTTAGCTG-3′ |
2.6. Determination of Cytoplasmic Vacuolization, Myofibrillar Loss, and Cardiac Hypertrophy

Hematoxylin and eosin (H&E) staining was performed for the evaluation of cytoplasmic vacuolization, myofibrillar loss, and cardiac hypertrophy through staining heart sections with hematoxylin (ThermoScientific Fisher; cat# 7211), acid alcohol 1% (Poly Scientific R&D Corp; cat# S104, Bay Shore, NY, USA), bluing (ThermoScientific Fisher; cat# 73011), and eosin (ThermoScientific Fisher; cat# 7111). Three sections/heart were examined, which were graded from 1 to 5, depending on the presence/absence of either cytoplasmic vacuolization or myofibrillar loss. Image J was used to quantify cardiomyocyte size (mm$^2$) at 20× magnification captured pictures.

2.7. Determination of Intestinal and Vascular Fibrosis

To examine vascular and interstitial fibrosis, Masson’s trichrome staining was performed to visualize fibrosis as previously published [6]. In brief, paraffin embedded heart tissues were cut into 5 µm serial sections and placed on slides. Following deparaffinization and rehydration, sections were incubated with Bouins fixative (45 min at 62.3 °C; Poly Scientific R&D Corp; cat# S129), and then stained with Weigert iron hematoxylin A&B solution (Poly Scientific R&D Corp; cat# S216 BA and S216 BB), Biebrich scarlet acid-fuscin (Poly Scientific R&D Corp; cat# S125), phosphomolybdic/phosphotungstic solution (Fisher; cat# A248-100, and A237-100), aniline blue (Poly Scientific R&D Corp; cat# S116), and 1% glacial acetic acid (Fisher; cat# A491-212). Interstitial fibrosis was quantified by measuring the total blue area per mm$^2$; while, vascular fibrosis was determined by measuring vascular fibrosis/vessel area × 100% on captured images at 20× magnification using NIH image J software.

2.8. Echocardiography

At day 14 (D14) after the last injection, 2D-echocardiography was performed using a Sonos 5500 ultrasonograph with a 15 MHz transducer (Philips, Andover MA). M-mode images were captured and analyzed as we published previously [6,11]. The left ventricular internal dimension-diastole (LVIDd), left ventricular internal dimension-systole (LVIDs), fractional shortening (FS; (LVIDd – LVIDs)/LVIDd × 100), left ventricular volume at end diastole (EDV), left ventricular volume at end systole (ESV), and ejection fraction (EF; (EDV– ESV)/EDV × 100)) were determined with and without ESCs or ES-Exos treatment in DIC.

2.9. Statistical Analysis

Data was analyzed using one-way analysis of variance (ANOVA) followed by a Tukey test and expressed as a mean ± SEM. The $p$-value < 0.05 denotes statistical significance.

3. Results

3.1. Effect of ESCs or ES-Exos on Mice Weight Following Dox Administration

To determine the impact of ESCs or ES-Exos on weight gain or weight loss, mice were weighed prior to the treatment as well as at the time of sacrifice (D14). As represented in Figure 1B, a significant ($p < 0.05$) weight loss was observed in Dox administered mice compared with controls. The weight loss was significantly ($p < 0.05$) improved with ESCs or ES-Exos treatment, suggesting that ESCs or ES-Exos attenuate Dox treatment adverse effects on whole body weight.

Ratio of heart weight to body weight was calculated as described previously [11]. Our data shows a significant ($p < 0.05$) increase in heart weight-to-body weight ratio in Dox administered mice as compared to control mice (Figure 1C). Moreover, treatment with ESCs or ES-Exos reduced the heart weight-to-body weight ratio significantly ($p < 0.05$), suggesting that ESCs or ES-Exos provide protective effects against Dox increased heart weight-to-body weight ratio. Furthermore, this data suggests that ES Exos, a subset of ESCs, have equal beneficial effects as compared to ESCs.
3.2. Expression of Inflammasome Formation Proteins (TLR4 and NLRP3) after ESCs or ES-Exos Treatment

IHC staining was performed to evaluate the expression of TLR4 and NLRP3 in cardiomyocytes following Dox treatment. The presence of TLR4+ve (Figure 2A,B) and NLRP3+ve (Figure 3A,B) cells were significantly ($p < 0.05$) increased in Dox treated group (f–j) compared with control (a–e). However, treatment with ESCs significantly reduced expression of TLR4 and NLRP3 positive cells (k–o). Upon comparing whether ES-Exos had a similar potential to decrease the expression of TLR4 and NLRP3 positive cardiomyocytes, our quantitative data shows ES-Exos significantly ($p < 0.05$) reduced the levels of TLR4 (Figure 2B) as well as NLRP3 (Figure 3B) expression.

To strengthen and confirm our IHC data of TLR4+ve and NLRP3+ve cardiomyocytes, we performed Western blot analysis. Our Western blot data shows a significant increase in TLR4 and NLRP3 compared to control ($p < 0.05$), and when Dox animals were treated with ESCs or ES-Exos, the expression of TLR4 and NLRP3 were significantly reduced ($p < 0.05$; Figures 2C and 3C, respectively). These changes in our Western blot analysis were further confirmed and quantified using densitometric analysis for TLR4 (Figure 2C) and NLRP3 (Figure 3C) markers. This set of TLR4 and NLRP3 data suggests Dox treatment enhanced inflammasome formation, which is attenuated with ESCs or ES-Exos.
3.3. Expression of Pyroptotic Markers Caspase-1, IL-1β, and IL-18, after ESCs or ES-Exos Treatment

To understand whether inflammasome protein formation can initiate pyroptosis, we performed immunofluorescence staining to determine the presence of pyroptotic markers caspase-1, IL-1β, and IL-18 [1,31]. First, our data shows Dox treated animals had significantly higher levels of caspase-1+ve cardiomyocytes compared with control animals (Figure 4A,B, p < 0.05). This increased number of positive cells was further decreased with ESCs or ES-Exos treatment. Next, we performed IL-1β staining to determine the effects of ESCs or ES-Exos treatment on IL-1β expression (Figure 4C,D). IHC staining of heart sections revealed a significant increase in the levels of IL-1β in Dox-treated animals compared with control (Figure 4C,D; p < 0.05). However, we observed Dox + ESCs or Dox + ES-Exos treated heart sections showed a significant decrease in the number of IL-1β+ve cells compared with Dox treated sections (p < 0.05). A third pyroptotic marker, IL-18, was stained to further confirm pyroptotic cell death in Dox treated hearts. Our IHC data showed a significant increase in IL-18+ve cells in Dox treated hearts compared with control (Figure 4E,F; p < 0.05). Noticeably, the animal groups that received ESCs or ES-Exos treatment showed significantly reduced numbers of IL-18+ve cells compared with Dox treated hearts (Figure 4F; p < 0.05).

To corroborate our immunofluorescence data, we performed Western blot analysis for caspase-1, IL-1β, and IL-18 with and without ESCs or ES-Exos administration (Figure 5). A significant increase in pyroptotic markers caspase-1 (Figure 5A), IL-1β (Figure 5B), and IL-18 (Figure 5C) was observed in Dox-treated animals compared with control (p < 0.05). The significant increase in expression of these pyroptotic markers was attenuated with ESCs or ES-Exos treatment (p < 0.05). Moreover, Western blot data was further confirmed through gene expression analysis for caspase-1 (Figure 5D), IL-1β (Figure 5E), and IL-18 (Figure 5F) using RT-PCR. Our data indicated a significant (p < 0.05) increase in gene expression following Dox administration in IL-1β (Figure 5E) and IL-18 (Figure 5F). An increased
trend of caspase-1 was observed but was not statistically significant. Moreover, this increase in these gene expressions was significantly \( p < 0.05 \) reduced upon treatment with ESCs or ES-Exos. Collectively, these results demonstrate significantly lower expression of pyroptotic markers caspase-1, IL-1β, and IL-18, suggesting ES-Exos contain specific factors capable of reducing pyroptosis in cardiomyocytes in vivo.

Figure 4. Treatment with ESCs or ES-Exos inhibits Dox-induced pyroptosis within the heart. (A) Representative photomicrographs of heart sections stained with src-α-actin and caspase-1. (C) Representative confocal microscopy of heart sections stained with src-α-actin and IL-1β. (E) Confocal imaging of heart sections co-stained with src-α-actin and IL-18. Individual boxes show Caspase-1\(^{+ve}\), IL-β\(^{+ve}\), and IL-18\(^{+ve}\) cells in red (a, f, k, p), cardiomyocytes in green (b, g, l, q), DAPI in blue (c, h, m, r), merged images (d, i, n, s), and enlarged areas of merged images (e, j, o, t). (B,D,F) Bar graphs derived from quantification of pyroptotic markers, caspase-1, IL-1β, and IL-18, respectively. Error bars = mean ± S.E.M. * \( p < 0.05 \) vs. control, # \( p < 0.05 \) vs. Dox, $ p = \text{non significant (NS)}$ Dox + ES-Exos vs. Dox + ESCs, one way ANOVA followed by a Tukey test, scale bar = 100 μm, \( n = 5–6 \).

Figure 5. ESCs or ES-Exos decrease pyroptotic markers expression following DIC. Representative blots and densitometric analysis for (A) Caspase-1, (B) IL-1β, and (C) IL-18. Quantitative RT-PCR data for (D) caspase-1, (E) IL-1β, and (F) IL-18. Error bars = mean ± S.E.M. * \( p < 0.05 \) vs. control, # \( p < 0.05 \) vs. Dox, $ p = \text{non significant (NS)}$ Dox + ES-Exos vs. Dox + ESCs, one way ANOVA followed by a Tukey test, Western blot quantities are expressed as A.U. \( n = 5–6 \) for Western blot, \( n = 3–4 \) for RT-PCR.
3.4. ES-Exos Reduces Pro-Inflammatory M1 Macrophages and Enhances Anti-Inflammatory M2 Macrophages

Differentiation of monocytes into M1 and M2 macrophages under pathological conditions has been well established [32–34]. To investigate whether ES-Exos treatment affects pro-inflammatory M1 Macrophages, IHC staining was performed for iNOS. Significantly \((p < 0.05)\) increased expression of iNOS positive cells was observed in the Dox treated group (f–j) versus control animals (a–e), whereas a significant \((p < 0.05)\) reduction in the number of iNOS positive cells was observed upon ESCs or ES-Exos treatment (Figure 6A,B). To compliment this data, we examined the presence of TNF-\(\alpha\), a previously reported pro-inflammatory cytokine [32,35]. IHC staining revealed a statistically significant \((p < 0.05)\) increase in TNF-\(\alpha^{+ve}\) cardiomyocytes (Figure 6C,D) in the Dox group (f–j) as compared with control (a–e), corroborating iNOS data. ESCs (k–o) or ES-Exos (p–t) treatment also showed significantly \((p < 0.05)\) reduced TNF-\(\alpha^{+ve}\) positive cells as expected in comparison to the Dox group (Figure 6C,D). Moreover, to confirm IHC data for TNF-\(\alpha\), western blot was performed. Densitometric analysis showed a significant \((p < 0.05)\) increase in TNF-\(\alpha\) expression following Dox administration, however co-treatment with ES-Exos reduced this protein expression significantly \((p < 0.05, \text{Figure 6E})\).

**Figure 6.** ESCs or ES-Exos treatment reduces M1 macrophages abundance as well as TNF-\(\alpha\) secretion. (A) Representative photomicrographs of heart sections stained with src-\(\alpha\)-actin and iNOS. (C) confocal microscopy images for TNF-\(\alpha\). Individual boxes show iNOS\(^{+ve}\) and TNF-\(\alpha^{+ve}\) cells in red (a, f, k, p), cardiomyocytes in green (b, g, l, q), DAPI in blue (c, h, m, r), merged images (d, i, n, s), and enlarged areas of merged images (e, j, o, t). (B) Quantitative analysis-derived histograms show positive cardiomyocytes for iNOS. (D) Bar graph resulted from quantitative analysis of TNF-\(\alpha\) (D). (E) Representative blot and densitometric analysis shown for TNF-\(\alpha\). Error bars = mean ± S.E.M. * \(p < 0.05\) vs. control, \# \(p < 0.05\) vs. Dox, \$ \(p =\) non significant (NS) Dox + ES-Exos vs. Dox + ESCs, one way ANOVA followed by a Tukey test, Western blot quantities are expressed as A.U. Scale bar = 100 \(\mu m\), \(n = 4–5\) for immunohistochemistry (IHC).

Next, we performed analysis for anti-inflammatory M2 macrophage abundance using CD206 immunostaining. Our staining data shows a reduction of M2 macrophages in Dox administered group (Figure 7A, f–j) as compared to control (Figure 7A, a–e), however, data was not statistically significant.
In comparison, ESCs or ES-Exos treatment significantly \( p < 0.05 \) increased the number of CD206 positive cells (Figure 7B) compared to Dox alone. To verify the increased anti-inflammatory actions upon ES-Exos treatment, we performed IHC staining for IL-10, an anti-inflammatory interleukin. Quantitative analysis showed a significant \( p < 0.05 \) decrease in IL-10\(^{+} \) cardiomyocytes (Figure 7C) in the Dox group as compared with control, suggesting decreased M2 macrophages may correlate with decreased IL-10 following Dox treatment. Dox co-treatment with ESCs or ES-Exos significantly \( p < 0.05 \) increased the number IL-10 positive cardiomyocytes compared to the Dox group (Figure 7C). Furthermore, western blot analysis corroborated with IL-10 IHC data, showing a significant \( p < 0.05 \) reduction in Dox group, whereas ES-Exos treatment significantly \( p < 0.05 \) upregulated IL-10 expression (Figure 7D).

 Altogether, these results suggest that ESCs or ES-Exos treatment reduces pro-inflammatory M1 macrophages and pro-inflammatory cytokine TNF-\( \alpha \). In addition, this decrease in pro-inflammatory M1 macrophages occurs with simultaneous stimulation of anti-inflammatory M2 macrophages and IL-10 release, suggesting infiltrated monocytes differentiate into M2 macrophages with ESCs or ES-Exos treatment and create an anti-inflammatory microenvironment in the heart that decreases inflammation and pyroptosis.
3.5. Effects of ESCs or ES-Exos Treatment on Mitogen-Activated Protein Kinase (MAPK) Cell Signaling

Current literature suggests that under inflammatory conditions, there is upregulation of cell signaling proteins MyD88, P38, and JNK [36,37]. The upregulation of these cell signaling proteins in Dox treated hearts with and without ESCs or ES-Exos remains unknown. To address these questions, western blot was performed. Our data suggests significantly ($p < 0.05$) increased MyD88 (Figure 8A), p-P38 (Figure 8B), and p-JNK (Figure 8C) in the Dox group compared to control animals. However, this significant increase in cell signaling proteins was reduced following ESCs or the ES-Exos treatment (Figure 8). Our data suggests that (1) Dox-induced pro-inflammatory microenvironment in the Dox treated hearts involves cell signaling proteins MyD88, p-P38, and p-JNK, (2) the induction of pyroptosis within the heart may include these cell signaling proteins, and (3) this process is mitigated with co-treatment of Dox with ESCs or ES-Exos.

![Figure 8](image)

**Figure 8.** Treatment with ESCs or ES-Exos downregulates mitogen-activated protein kinase (MAPK) signaling pathway in the DIC mouse model. (A–C) Representative blots and densitometric analysis are shown for (A) MyD88, (B) p-P38, and (C) p-JNK. Error bars = mean ± S.E.M. * $p < 0.05$ vs. control, $^\# p < 0.05$ vs. Dox, $^S p = $ non significant (NS) Dox + ES-Exos vs. Dox + ESCs, one way ANOVA followed by a Tukey test, Western blot quantities are expressed as A.U. $n = 5–6$.

3.6. Effects of ESCs or ES-Exos on Cytoplasmic Vacuolization, Myofibril Loss, and Cardiac Hypertrophy

It has already been published that Dox can cause significant structural changes to myocardium including cytoplasmic vacuolization, myofibril loss, and cardiac hypertrophy [24,25,29]. To assess the impact of ESCs or ES-Exos on cardiac remodeling and structural changes in DIC heart, we stained heart sections with hematoxylin and eosin (H&E). Our data shows cytoplasmic vacuolization and myofibril loss was significantly ($p < 0.05$) increased in the Dox group compared to controls (Figure 9B,C, respectively), suggesting the heart has developed cardiac dysfunction. In comparison, ESCs or the ES-Exos treatment significantly reduced the vacuolization and myofibril loss (Figure 9B,C, respectively, $p < 0.05$).

Published studies suggest that there is an increase in cardiomyocyte size during cardiac remodeling following Dox treatment [11,38]. Hypertrophy is a cardioprotective, adaptive mechanism characterized by thickening of the heart muscle accompanied by subsequent diminished cardiac output. To evaluate whether ES-Exos treatment reduces hypertrophy of cardiomyocytes in the DIC heart, H&E stained slides were further analyzed (Figure 10). The cardiomyocyte area was significantly ($p < 0.05$) increased in the Dox group compared to the controls (Figure 10B). In contrast, mice treated with ESCs or ES-Exos showed cardiomyocytes significantly ($p < 0.05$) smaller in size compared with Dox administered mice (Figure 10B). Overall, this data suggest that ESCs or ES-Exos significantly reduced the Dox induced cytoplasmic vacuolization, myofibril loss, and cardiac hypertrophy.
Fibrosis is a widely accepted adverse remodeling mechanism that occurs following Dox treatment [6,19]. Masson’s trichrome staining was performed to quantify the collagen deposition during cardiac remodeling. Representative photomicrographs Figure 11A shows vascular fibrosis (a–d) and interstitial fibrosis (e–h) in control mice, Dox treated animals, and treated groups with ESCs or ES-Exos. The percentage of fibrosis was significantly ($p < 0.05$) increased in Dox administered hearts as compared to control, however, the animals treated with ESCs or ES-Exos significantly ($p < 0.05$) reduced both vascular and interstitial fibrosis (Figure 11B,C, respectively).

**3.7. Effects of ESCs or ES-Exos on Fibrosis and Pro-Fibrotic Protein MMP-9**

Fibrosis is a widely accepted adverse remodeling mechanism that occurs following Dox treatment [6,19]. Masson’s trichrome staining was performed to quantify the collagen deposition during cardiac remodeling. Representative photomicrographs Figure 11A shows vascular fibrosis (a–d) and interstitial fibrosis (e–h) in control mice, Dox treated animals, and treated groups with ESCs or ES-Exos. The percentage of fibrosis was significantly ($p < 0.05$) increased in Dox administered hearts as compared to control, however, the animals treated with ESCs or ES-Exos significantly ($p < 0.05$) reduced both vascular and interstitial fibrosis (Figure 11B,C, respectively).

**Figure 9.** ESCs or ES-Exos inhibit vacuolization and muscle cell loss post-Dox administration. (A) Representative images of hematoxylin and eosin (H&E) stained heart sections for all treatment groups are shown. (B) Quantitative analysis for cytoplasmic vacuolization. (C) Quantitative analysis for myofibril loss. Error bars = mean ± S.E.M. * $p < 0.05$ vs. control, # $p < 0.05$ vs. Dox, $^\#$ $p = \text{non significant (NS)}$ Dox + ES-Exos vs. Dox + ESCs, one way ANOVA followed by a Tukey test, scale bar = 100 µm, $n = 6–7$. Images taken at 40×.

**Figure 10.** ESCs or ES-Exos protects the heart from Dox-induced hypertrophy. (A) Representative cardiomyocyte photomicrographs of H&E stained heart sections for all treatment groups. (B) Quantitative analysis for cardiac hypertrophy. Error bars = mean ± S.E.M. * $p < 0.05$ vs. control, # $p < 0.05$ vs. Dox, $^\#$ $p = \text{non significant (NS)}$ Dox + ES-Exos vs. Dox + ESCs, one way ANOVA followed by a Tukey test, scale bar = 100 µm, $n = 5–6$. Images taken at 20×.
MMP-9 has been considered as a potential marker for extracellular matrix (ECM) degradation that is associated with fibrosis [11,39]. Therefore, we examined expression of MMP-9 to confirm fibrosis. Our western blot data shows a significant ($p < 0.05$) increase in MMP-9 expression in Dox treated animals as compared to control (Figure 11D). Following treatment with ESCs or ES-Exos the expression level of MMP-9 reduced significantly, ($p < 0.05$) compared with Dox group (Figure 11D). These results suggest that ESCs or ES-Exos treatment decreases both vascular and interstitial fibrosis as well as extracellular pro-fibrotic protein MMP-9 in the Dox-induced cardiomyopathy heart.

### 3.8. ES-Exos Improves Heart Function in DIC Murine Model

To determine the impact of ES-Exos on heart function, 2D transthoracic echocardiography was performed on D14 to evaluate various cardiovascular parameters, including LVIDd, LVIDs, EDV, ESV, FS (measurement of contractility), and EF (measurement of blood ejection from the ventricle) on all control and experimental mice. Analysis of echocardiography data revealed that Dox administered mice have significantly ($p < 0.05$) high values of LVIDd (Figure 12A), LVIDs (Figure 12B), EDV (Figure 12D), and ESV (Figure 12E) compared to the control group. Interestingly, animals treated with ESCs or ES-Exos demonstrated significantly ($p < 0.05$) improved cardiac function as compared to the Dox group, which was measured with LVIDd, LVIDs, EDV, and ESV. FS as an indicator of cardiac contractility and EF that measures left ventricular (LV) blood ejection in the heart were significantly ($p < 0.05$) reduced in Dox treated animals demonstrating decreased cardiac function (Figure 12C,F, respectively). This decreased FS and EF was improved significantly ($p < 0.05$) in the animal treated with ESCs or ES-Exos.

Note: We have performed statistical analysis in all the experiments to understand whether ESCs vs. ES-Exos are statistically different. We did not observe any statistically significant difference between ESCs and ES-Exos and data is reported in the Figures and Figure legends respectively.
4. Discussion

Stem cells have been widely used to treat various animal and human cardiac disorders [19,40,41]. Most animal studies associated with stem cell therapy have successfully demonstrated significant repair, regeneration, and cardiac function improvement [19,42,43]. Bone marrow-derived mesenchymal stem cells or embryonic stem cell-derived cardiomyocytes have been shown to repair injured myocardial infarcted heart, ischemic reperfusion injury, and Dox-induced heart failure in mice and rabbits [19,44–46]. Adult stem cell clinical studies in patients suffering from heart failure have shown mixed responses on the improvement of heart function [19,47]. In addition, ESC-derived cardiomyocytes or vascular smooth muscle cells have been shown to be an optimal cell type for cardiac cell therapy compared with adult stem cells [19,48]. However, the hope for ESC therapy was hampered when published reports showed potential chances of tumor formation [20,49,50].

Recent discovery of a cell-free system using Exos have generated a new era in cell therapy for cardiac repair and regeneration [23,28]. Current reports suggest that derived Exos from ESCs can regenerate infarcted heart, enhance myocardial viability and attenuate adverse cardiac remodeling in ischemic conditions [28]. Similarly, isolated Exos from adult stem cells, cardiac progenitor cells, and cardiac stem cells have shown protective effects against ischemic myocardium from apoptosis and adverse cardiac remodeling [1,51–54]. However, it remains unknown whether Exos isolated from ESCs have a potential to inhibit (1) inflammation-induced cell death: Pyroptosis, (2) attenuate inflammatory M1 macrophage abundance, (3) enhance anti-inflammatory M2 macrophage population, and (4) reduce Dox-induced adverse cardiac remodeling including cytoplasmic vacuolization, myofibrillar loss, cardiac hypertrophy, and fibrosis. We further evaluated the effects of these ES-Exos on cardiac dysfunction induced by Dox.

We recently reported in our cell culture system that Dox induces TLR4-NLRP3 mediated pyroptosis in H9c2 cells [1]; however, this remains unknown whether pyroptosis occurs in an in vivo model of DIC. The current study investigates the presence of pyroptosis in DIC in vivo, focuses on understanding the effects of transplanted ES-Exos and compares the beneficial effects of ES-Exos vs. ESCs. Pyroptosis is an inflammation-mediated cell death that is believed to occur when there is a bacterial infection initiating inflammation [55]. Recent studies show that Salmonella and Shigella species caused caspase-1 mediated pyroptosis in macrophages that results in the release of IL-1β and IL-18 [55–57].
However, published study reports that NLRP3 inflammasome-mediated pyroptosis occurs in diabetic rats following ischemic reperfusion injury within the heart where pyroptosis was not initiated by a bacterial infection [58]. Therefore, it is hypothesized that pyroptosis present in non-infectious tissues such as heart is initiated through DAMPs (damage-associated molecular pattern molecules) termed as sterile inflammation. The sterile inflammation-induced pyroptosis is initiated through activation of the TLR4 receptor, which results in the formation of the NLRP3 inflammasome as published previously [59–61]. This response induces the activation of the caspase-1 cascade and causes downstream secretion of pro-inflammatory cytokines IL-1β and IL-18 as observed in diabetic infarcted hearts [31,60,61]. In the present study, a DIC model of pyroptosis was generated in C57BL/6J mice and was confirmed via the upregulated presence of inflammasome markers (TLR4 and NLRP3). Furthermore, we examined presence of pyroptotic markers caspase-1, IL-1β, and IL-18 using immunohistochemistry and western blot analysis that indicated significant (p < 0.05) upregulation of these markers and confirmed pyroptosis as reported by various investigators [31,58,60,62]. Moreover, ES-Exos used in the present study inhibits TLR4 and NLRP3 inflammasome markers and inflammasome-induced pyroptosis in DIC. These in vivo data in DIC are in conjunction with our previously published reports on ES-Exos demonstrating inhibition of the inflammasome and pyroptotic proteins in Dox-induced pyroptosis in H9c2 [1] and Sol 8 [29] cells.

Next, we examined the presence of pro and anti-inflammatory cytokines as well as hypothesized whether Dox-induced cardiomyocyte apoptosis or necrosis cause infiltration of monocytes to clear dying cardiomyocytes, which were unable to be cleared naturally. Our data confirmed presence of significantly increased M1 macrophages in DIC heart and generated a pro-inflammatory microenvironment, which was further confirmed with secretion of pro-inflammatory cytokine, TNF-α. Whether this increased M1 macrophage level might have caused inflammation-mediated pyroptosis in DIC hearts remains unknown and requires further investigation.

Interestingly, ES-Exos enhanced anti-inflammatory M2 macrophages in DIC, which is in corroborated with other previously published literature on the effects of Exos on macrophage polarization [63–65]. Moreover, this increased M2 macrophage level created an anti-inflammatory microenvironment, which was confirmed with the presence of anti-inflammatory cytokine IL-10. The transplanted ES-Exos also inhibited inflammasome and pyroptotic markers compared with Dox-treated hearts as mentioned above. Therefore, these findings raises an important question about the specific contents of Exos including miRNA, growth factors, proteins, and anti-inflammatory cytokines that may play a role in converting M1 into M2 macrophages or directly inhibiting pyroptosis in DIC heart. Our recently published data showed ES-Exos predominantly enriched with anti-inflammatory cytokines [1]. However, this remains unknown whether these anti-inflammatory cytokines in these ES-Exos inhibit pyroptosis or enhance M2 macrophages specifically.

Moreover, we investigated the possible cell signaling pathway involved in pyroptosis in DIC hearts with and without ES-Exos treatment. Our data shows pro-inflammatory cell signaling proteins MyD88, p-P38, and p-JNK following inflammation were significantly increased in DIC, which is in agreement with previously published studies [66–68]. Following treatment with ESCs or ES-Exos, we observed for the first time a reduction in cell signaling proteins, which might have played a role in decreased pyroptosis in DIC.

According to recently published literature, DIC heart shows cytoplasmic vacuolization, myofibril loss, and hypertrophy of cardiomyocytes (hallmarks of cardiomyopathy), where these alterations preserve the architecture of the heart [11,19]. However, these changes further enhance cardiac fibrosis involving MMPs-induced ECM degradation and leads to cardiac dysfunction [6,11,19]. Therefore, we hypothesized whether treatment with ES-Exos can inhibit cytoplasmic vacuolization, myofibril loss, and hypertrophy as well as cardiac fibrosis, a major contributor in DIC leading to heart failure. To the best of our knowledge, there are no published studies demonstrating that ES-Exos can preserve cardiac architecture by inhibiting cytoplasmic vacuolization, myofibril loss, hypertrophy, and fibrosis in DIC hearts. The observed vascular fibrosis in DIC heart was intense in the vascular and peripheral area of the vessels whereas interstitial fibrosis in these hearts was sporadic (Figure 11).
This significant increase in fibrosis was inhibited by ES-Exos. Furthermore, we observed significant reduction in ECM degradation protein, MMP9. Therefore, this set of data concludes that ES-Exos has the potential to inhibit adverse cardiac remodeling in DIC hearts. However, the mechanisms of inhibition of adverse cardiac remodeling with ES-Exos remain elusive.

After inhibition of inflammation-induced pyroptosis and adverse cardiac remodeling following ES-Exos transplantation, we determined whether these Exos have any effects on cardiac dysfunction observed following Dox treatment. Interestingly, our data shows ES-Exos significantly ($p < 0.05$) improved Dox-induced cardiac dysfunction (Figure 12).

Moreover, recent studies suggest that intraperitoneally (i.p.) transplanted stem cells or derived exosomes showed protection in cardiac and many other diseases [19,69–73] The current study uses i.p. injections to administer ESCs or ES-Exos and shows inhibition of pyroptosis and adverse cardiac remodeling in DIC. Therefore, our data corroborates with the previously published studies as stated above that used i.p injection to administer stem cells or derived exosomes. However, this would be interesting and open a new door to inject ESCs or ES-Exos using intravenous (i.v.) injections to determine whether i.v. injections have different protective effects on cardiac remodeling in DIC.

In conclusion, the current study provided evidence that Dox induced pyroptosis and inflammation, which could be inhibited upon treatment with ES-Exos leading to overall preservation of cardiac function, presented in schematic diagram (Figure 13). This was a novel study with new mechanistic observations on the pathophysiological role of pyroptosis in Dox-induced cardiotoxicity. Additionally, this study emphasized whether ES-Exos had equal potential compared with ESCs used in cell therapy. Our data on ES-Exos and ESCs shows inhibition of pyroptosis, cell signaling, adverse cardiac remodeling, and improved heart function with equal in quality and quantity. Therefore, this cell-free system, ES-Exos, could be a future therapeutic agent in clinical investigations without losing any potential benefits compared to ESCs where we had no further threat of teratoma formation.

**Figure 13.** Treatment with ES-Exos reduces Dox-induced heart dysfunction. Schematic picture represents that Dox induces pyroptosis and increases inflammation via enhanced M1 macrophage population. However, treatment with ES-Exos can attenuate pyroptosis, increase M2 macrophage polarization and anti-inflammatory cytokine release (IL-10), which is potentially mediated through some anti-inflammatory cytokines present in ES-Exos. ER; endoplasmic reticulum, DAMPs; damage-associated molecular pattern molecules, TLR4; toll-like receptor 4, NLRP3; nucleotide-binding oligomerization domain-like receptor pyrin domain containing-3.
Author Contributions: D.K.S. designed and supervised the study. T.A.J. and Z.T.D. performed the experiments, analyzed data, and prepared figures. Z.T.D. drafted the manuscript. D.K.S. revised the manuscript and approved final version of the manuscript. T.A.J. current correspondence is johnson.tayl18@students.ecu.edu.

Funding: This study was supported in part by National Institutes of Health Grant R01-CA-221813 and internal endowed chair support to D.K. Singla.

Acknowledgments: The author would like to thank Fatima Bianca Dessouki and Chandrakala Aluganti for technical assistance and proof reading of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

ANOVA analysis of variance
BW body weight
DAPI 4′,6-diamino-2-phenylindole
DIC doxorubicin-induced cardiotoxicity
DMEM dulbecco’s modified eagle’s medium
Dox doxorubicin
EDV end diastolic volume
EF ejection fraction
ER endoplasmic reticulum
ESCs embryonic stem cells
ESV end systolic volume
Exos exosomes
FBS fetal bovine serum
FS fractional shortening
H&E hematoxylin and eosin
HW heart weight
IHC immunohistochemistry
IL interleukin
iNOS induced nitric oxide synthase
IP intraperitoneal
LVIDd left ventricular internal dimension-diastole
LVIDs left ventricular internal dimension-systole
MI myocardial infarction
miRNA microRNA
MMP matrix metalloproteinase
PBS phosphate buffered saline
PS penicillin/streptomycin
PVDF polyvinylidene difluoride
RIPA radio-immunoprecipitation assay
RT-PCR real time-polymerase chain reaction
Src-α-actin sarcomeric alpha actin
SDS sodium dodecyl sulfate
SEM standard error of mean

References

1. Tavakoli Dargani, Z.; Singla, D.K. Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis. Am. J. Physiol. Heart Circ. Physiol. 2019, 317, H460–H471. [CrossRef] [PubMed]

2. Thorn, C.F.; Oshiro, C.; Marsh, S.; Hernandez-Boussard, T.; McLeod, H.; Klein, T.E.; Altman, R.B. Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenetics Genom. 2011, 21, 440–446. [CrossRef] [PubMed]
3. Octavia, Y.; Tocchetti, C.G.; Gabrielson, K.L.; Janssens, S.; Crijs, H.J.; Moens, A.L. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. *J. Mol. Cell. Cardiol.* 2012, 52, 1213–1225. [CrossRef]

4. Jain, D.; Ahmad, T.; Cairo, M.; Aronow, W. Cardiotoxicity of cancer chemotherapy: Identification, prevention and treatment. *Ann. Transl. Med.* 2017, 5, 348. [CrossRef]

5. Zhang, Y.-W.; Shi, J.; Li, Y.-J.; Wei, L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. *Arch. Immunol. et Ther. Exp.* 2009, 57, 435–445. [CrossRef] [PubMed]

6. Merino, H.; Singla, D.K. Notch-1 Mediated Cardiac Protection following Embryonic and Induced Pluripotent Stem Cell Transplantation in Doxorubicin-Induced Heart Failure. *PLoS ONE* 2014, 9, e101024. [CrossRef] [PubMed]

7. Chatterjee, K.; Zhang, J.; Honbo, N.; Karliner, J.S. Doxorubicin cardiomyopathy. *Cardiology* 2010, 115, 155–162. [CrossRef] [PubMed]

8. Singla, D.K. Akt—mTOR Pathway Inhibits Apoptosis and Fibrosis in Doxorubicin-Induced Cardiotoxicity following Embryonic Stem Cell Transplantation. *Cell Transplant.* 2015, 24, 1031–1042. [CrossRef] [PubMed]

9. Wu, S. Adriamycin-induced Cardiomyocyte and Endothelial Cell Apoptosis: In Vitro and In Vivo Studies. *J. Mol. Cell. Cardiol.* 2002, 34, 1595–1607. [CrossRef] [PubMed]

10. Johnson, T.A.; Singla, D.K. PTEN inhibitor VO-OHpic attenuates inflammatory M1 macrophages and cardiac remodeling in doxorubicin-induced cardiomyopathy. *Am. J. Physiol. Circ. Physiol.* 2018, 315, H1236–H1249. [CrossRef] [PubMed]

11. Abdel-Raheem, I.T.; Taye, A.; Abouzied, M.M.; Abdel-Raheem, I.T. Cardioprotective Effects of Nicorandil, a Mitochondrial Potassium Channel Opener against Doxorubicin-Induced Cardiotoxicity in Rats. *Basic Clin. Pharmacol. Toxicol.* 2013, 113, 158–166. [CrossRef] [PubMed]

12. Kalyanaraman, B.; Kotamraju, S.; Konorev, E.A.; Joseph, J. Doxorubicin-induced Apoptosis in Endothelial Cells and Cardiomyocytes Is Ameliorated by Nitrone Spin Traps and Ebselen. *J. Biol. Chem.* 2000, 275, 33585–33592.

13. Mohajeri, M.; Sahebkar, A. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review. *Crit. Rev. Oncol. Hematol.* 2018, 122, 30–51. [CrossRef]

14. Priya, L.B.; Baskaran, R.; Huang, C.Y.; Padma, V.V. Neferine ameliorates cardiomyoblast apoptosis induced by doxorubicin: Possible role in modulating NADPH oxidase/ROS-mediated NFkappaB redox signaling cascade. *Sci. Rep.* 2017, 7, 12283. [CrossRef] [PubMed]

15. QuanJun, Y.; Genjin, Y.; Lili, W.; Yonglong, H.; Yan, H.; Jie, L.; Jinlu, H.; Jin, L.; Run, G.; Cheng, G. Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolic Study. *PLoS ONE* 2017, 12, e0169567. [CrossRef]

16. Tian, X.-Q.; Ni, X.-W.; Xu, H.-L.; Zheng, L.; Zhuge, D.-L.; Chen, B.; Lu, C.-T.; Yuan, J.-J.; Zhao, Y.-Z. Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction. *Int. J. Nanomed.* 2017, 12, 7103–7119. [CrossRef]

17. Viswanatha Swamy, A.H.; Wangikar, U.; Koti, B.C.; Thippeswamy, A.H.; Ronad, P.M.; Manjula, D.V. Cardioprotective effect of ascorbic acid on doxorubicin-induced myocardial toxicity in rats. *Indian J. Pharmacol.* 2011, 43, 507–511. [CrossRef]

18. Singla, D.K.; Ahmed, A.; Singla, R.; Yan, B. Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. *Cell Transplant.* 2012, 21, 1919–1930. [CrossRef]

19. Nussbaum, J.; Minami, E.; Laflamme, M.A.; Virag, J.A.I.; Ware, C.B.; Masino, A.; Mushkeli, V.; Pabon, L.; Reinecke, H.; Murry, C.E. Transplantation of undifferentiated murine embryonic stem cells in the heart: Teratoma formation and immune response. *FASEB J.* 2007, 21, 1345–1357. [CrossRef]

20. Swijnenburg, R.-J.; Tanaka, M.; Vogel, O.H.; Baker, J.; Kofidis, T.; Gunawan, F.; Lebl, D.R.; Caffarelli, A.D.; De Bruin, J.L.; Fedoseyeva, E.V.; et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. *Circulation* 2005, 112, I166–I172. [PubMed]

21. Abdelwahid, E.; Kalvelyte, A.; Stulpinas, A.; De Carvalho, K.A.T.; Guarita-Souza, L.C.; Földes, G. Stem cell death and survival in heart regeneration and repair. *Apoptosis* 2016, 21, 252–268. [CrossRef] [PubMed]
23. Singla, D.K. Stem cells and exosomes in cardiac repair. *Curr. Opin. Pharmacol.* 2016, 27, 19–23. [CrossRef] [PubMed]

24. Ong, S.G.; Wu, J.C. Exosomes as potential alternatives to stem cell therapy in mediating cardiac regeneration. *Circ. Res.* 2015, 117, 7–9. [CrossRef] [PubMed]

25. Ibrahim, A.G.-E.; Cheng, K.; Marbán, E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. *Stem Cell Rep.* 2014, 2, 606–619. [CrossRef]

26. Zhang, Y.; Liu, Y.; Liu, H.; Tang, W.H. Exosomes: Biogenesis, biologic function and clinical potential. *Cell Biosci.* 2019, 9, 19. [CrossRef] [PubMed]

27. Jella, K.K.; Nasti, T.H.; Li, Z.; Malla, S.R.; Buchwald, Z.S.; Khan, M.K. Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy. *Vaccines* 2018, 6, 69. [CrossRef]

28. Khan, M.; Nickoloff, E.; Abramova, T.; Johnson, J.; Verma, S.K.; Krishnamurthy, P.; Mackie, A.R.; Vaughan, E.; Garikipati, V.N.S.; Benedict, C.; et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. *Circ. Res.* 2015, 117, 52–64. [CrossRef] [PubMed]

29. Tavakoli Dargani, Z.; Singla, R.; Johnson, T.; Kukreja, R.; Singla, D.K. Exosomes derived from embryonic stem cells inhibit doxorubicin and inflammation-induced pyroptosis in muscle cells. *Can. J. Physiol. Pharmacol.* 2018, 96, 304–307. [CrossRef] [PubMed]

30. Yan, B.; Singla, R.D.; Abdelli, L.S.; Singal, P.K.; Singla, D.K. Regulation of PTEN/Akt pathway enhances cardiomyogenesis and attenuates adverse left ventricular remodeling following thymosin beta4 Overexpressing embryonic stem cell transplantation in the infarcted heart. *PLoS ONE* 2013, 8, e75580. [CrossRef] [PubMed]

31. Miao, E.A.; Rajan, J.V.; Aderem, A. Caspase-1-induced pyroptotic cell death. *Immunol. Rev.* 2011, 243, 206–214. [CrossRef] [PubMed]

32. Singla, D.K.; Singla, R.D.; Abdelli, L.S.; Glass, C. Fibroblast Growth Factor-9 Enhances M2 Macrophage Differentiation and Attenuates Adverse Cardiac Remodeling in the Infarcted Diabetic Heart. *PLOS ONE* 2015, 10, e0120739. [CrossRef] [PubMed]

33. Parisi, L.; Gini, E.; Baci, D.; Tremolati, M.; Fanuli, M.; Bassani, B.; Farronato, G.; Bruno, A.; Mortara, L. Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders? *J. Immunol. Res.* 2018, 2018, 1–25. [CrossRef] [PubMed]

34. Urbina, P.; Singla, D.K. BMP-7 attenuates adverse cardiac remodeling mediated through M2 macrophages in prediabetic cardiomyopathy. *Am. J. Physiol. Circ. Physiol.* 2014, 307, H762–H772. [CrossRef] [PubMed]

35. Tian, M.; Yuan, Y.C.; Li, J.Y.; Gionfriddo, M.R.; Huang, R.C. Tumor necrosis factor-alpha and its role as a mediator in myocardial infarction: A brief review. *Chronic. Dis. Transl. Med.* 2015, 1, 18–26. [CrossRef]

36. Zou, J.; Shankar, N. Roles of TLR/MyD88/MAPK/NF-kappaB Signaling Pathways in the Regulation of Phagocytosis and Proinflammatory Cytokine Expression in Response to E. faecalis Infection. *PLoS ONE* 2015, 10, e0136947. [CrossRef] [PubMed]

37. Marchant, D.; Singhera, G.K.; Utokaparch, S.; Hackett, T.L.; Boyd, J.H.; Luo, Z.; Si, X.; Dorsch, D.R.; McManus, B.M.; Hegele, R.G. Toll-Like Receptor 4-Mediated Activation of p38 Mitogen-Activated Protein Kinase Is a Determinant of Respiratory Virus Entry and Tropism. *J. Virol.* 2010, 84, 11359–11373. [CrossRef]

38. Du, Q.; Zhu, B.; Zhai, Q.; Yu, B. Sirt3 attenuates doxorubicin-induced cardiac hypertrophy and mitochondrial dysfunction via suppression of Bnip3. *Am. J. Transl. Res.* 2017, 9, 3360–3373.

39. Glass, C.; Singla, D.K. MicroRNA-1 transfected embryonic stem cells enhance cardiac myocyte differentiation and inhibit apoptosis by modulating the PTEN/Akt pathway in the infarcted heart. *Am. J. Physiol. Circ. Physiol.* 2011, 301, H2038–H2049. [CrossRef]

40. Faiella, W.; Atoui, R. Therapeutic use of stem cells for cardiovascular disease. *Clin. Transl. Med.* 2016, 5, 34. [CrossRef]

41. Sun, R.; Li, X.; Liu, M.; Zeng, Y.; Chen, S.; Zhang, P. Advances in stem cell therapy for cardiovascular disease (Review). *Int. J. Mol. Med.* 2016, 38, 23–29. [CrossRef] [PubMed]

42. Yan, B.; Singla, D.K. Transplanted Induced Pluripotent Stem Cells Mitigate Oxidative Stress and Improve Cardiac Function through the Akt Cell Survival Pathway in Diabetic Cardiomyopathy. *Mol. Pharm.* 2013, 10, 3425–3432. [CrossRef] [PubMed]
43. Orlic, D.; Kajstura, J.; Chimenti, S.; Jakoniuk, I.; Anderson, S.M.; Li, B.; Pickel, J.; McKay, R.; Nadal-Ginard, B.; Bodine, D.M.; et al. Bone marrow cells regenerate infarcted myocardium. *Nature* 2001, 410, 701–705. [CrossRef] [PubMed]

44. Abushouk, A.I.; Salem, A.M.A.; Saad, A.; Afifi, A.M.; Afify, A.Y.; Afify, H.; Salem, H.S.; Ghanem, E.; Abdel-Daim, M.M. Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate. *Front. Pharmacol.* 2019, 10. [CrossRef] [PubMed]

45. Chen, R.; Cai, X.; Liu, J.; Bai, B.; Li, X. Sphingosine 1-phosphate promotes mesenchymal stem cell-mediated cardioprotection against myocardial infarction via ERK1/2-MMP-9 and Akt signaling axis. *Life Sci.* 2018, 215, 31–42. [CrossRef] [PubMed]

46. Garbade, J.; Dhein, S.; Lipinski, C.; Aupperle, H.; Arsalan, M.; Borger, M.A.; Barten, M.J.; Lehmann, S.; Walther, T.; Mohr, F.-W. Bone Marrow-Derived Stem Cells Attenuate Impaired Contractility and Enhance Capillary Density in a Rabbit Model of Doxorubicin-Induced Failing Hearts. *J. Card. Surg.* 2009, 24, 591–599. [CrossRef] [PubMed]

47. Haider, H.; Ashraf, M. Bone marrow cell transplantation in clinical perspective. *J. Mol. Cell. Cardiol.* 2005, 38, 225–235. [CrossRef] [PubMed]

48. Du Pre, B.C.; Doevendans, P.A.; van Laake, L.W. Stem cells for cardiac repair: An introduction. *J. Geriatr. Cardiol.* 2013, 10, 186–197. [PubMed]

49. Blum, B.; Benvenisty, N. The Tumorigenicity of Human Embryonic Stem Cells. *Adv. Cancer Res.* 2008, 100, 133–158. [PubMed]

50. Hentze, H.; Soong, P.L.; Wang, S.T.; Phillips, B.W.; Putti, T.C.; Dunn, N.R. Teratoma formation by human embryonic stem cells: Evaluation of essential parameters for future safety studies. *Stem Cell Res.* 2009, 2, 198–210. [CrossRef] [PubMed]

51. Arslan, F.; Lai, R.C.; Smeets, M.B.; Akeroyd, L.; Choo, A.; Aguor, E.N. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. *Stem Cell Res.* 2013, 10, 301–312. [CrossRef] [PubMed]

52. Xiao, J.; Pan, Y.; Li, X.H.; Yang, X.Y.; Feng, Y.L.; Tan, H.H.; Jiang, L.; Feng, J.; Yu, X.Y. Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4. *Cell Death Dis.* 2016, 7, e2277. [CrossRef] [PubMed]

53. Barile, L.; Milano, G.; Vassalli, G. Beneficial effects of exosomes secreted by cardiac-derived progenitor cells and other cell types in myocardial ischemia. *Stem Cell Investig.* 2017, 4, 93. [CrossRef] [PubMed]

54. Yuan, Y.; Du, W.; Liu, J.; Ma, W.; Zhang, L.; Du, Z.; Cai, B. Stem Cell-Derived Exosome in Cardiovascular Diseases: Macro Roles of Micro Particles. *Front. Pharmacol.* 2018, 9. [CrossRef] [PubMed]

55. Latz, E.; Xiao, T.S.; Stutz, A. Activation and regulation of the inflammasomes. *Nat. Rev. Immunol.* 2013, 13, 397–411. [CrossRef]

56. Fleetwood, A.J.; Lee, M.K.; Singleton, W.; Achuthan, A.; Lee, M.-C.; O’Brien-Simpson, N.M.; Cook, A.D.; Murphy, A.J.; Dashper, S.G.; Reynolds, E.C.; et al. Metabolic Remodeling, Inflammasome Activation, and Pyroptosis in Macrophages Stimulated by Porphyromonas gingivalis and Its Outer Membrane Vesicles. *Front. Microbiol.* 2017, 7, 351. [CrossRef]
61. Dong, W.; Zhu, Q.; Yang, B.; Qin, Q.; Wang, Y.; Xia, X.; Zhu, X.; Liu, Z.; Song, E.; Song, Y. Polychlorinated Biphenyl Quinone Induces Caspase 1-Mediated Pyroptosis through Induction of Pro-inflammatory HMG1-TLR4-NLRP3-GSDMD Signal Axis. Chem. Res. Toxicol. 2019, 32, 1051–1057. [CrossRef] [PubMed]

62. Man, S.M.; Karki, R.; Kanneganti, T.-D. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol. Rev. 2017, 277, 61–75. [CrossRef] [PubMed]

63. Deng, S.; Zhou, X.; Ge, Z.; Song, Y.; Wang, H.; Liu, X.; Zhang, D. Exosomes from adipose-derived mesenchymal stem cells ameliorate cardiac damage after myocardial infarction by activating S1P/S1PR1 signaling and promoting macrophage M2 polarization. Int. J. Biochem. Cell Biol. 2019, 114, 105564. [CrossRef] [PubMed]

64. Cai, J.; Qiao, B.; Gao, N.; Lin, N.; He, W. Oral squamous cell carcinoma-derived exosomes promote M2 subtype macrophage polarization mediated by exosome-enclosed miR-29a-3p. Am. J. Physiol. Physiol. 2019, 316, C731–C740. [CrossRef] [PubMed]

65. Bardi, G.T.; Smith, M.A.; Hood, J.L. Melanoma exosomes promote mixed M1 and M2 macrophage polarization. Cytokine 2018, 105, 63–72. [CrossRef]

66. El-Agamy, D.S.; El-Harbi, K.M.; Khoshhal, S.; Ahmed, N.; Elkablawy, M.A.; Shaaban, A.A.; Abo-Haded, H.M. Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways. Cancer Manag. Res. 2019, 11, 47–61. [CrossRef] [PubMed]

67. Kaminska, B.; Gozdz, A.; Zawadzka, M.; Ellert-Miklaszewska, A.; Lipko, M. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat. Rec. 2009, 292, 1902–1913. [CrossRef]

68. Zhang, B.; Ramesh, G.; Uematsu, S.; Akira, S.; Reeves, W.B. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J. Am. Soc. Nephrol. 2008, 19, 923–932. [CrossRef]

69. Ramalho, B.D.S.; De Almeida, F.M.; Sales, C.M.; De Lima, S.; Martinez, A.M.B. Injection of bone marrow mesenchymal stem cells by intravenous or intraperitoneal routes is a viable alternative to spinal cord injury treatment in mice. Neural Regen. Res. 2018, 13, 1046–1053.

70. Wang, M.; Liang, C.; Hu, H.; Zhou, L.; Xu, B.; Wang, X.; Han, Y.; Nie, Y.; Jia, S.; Liang, J.; et al. Intraperitoneal injection (IP), Intravenous injection (IV) or anal injection (AI)? Best way for mesenchymal stem cells transplantation for colitis. Sci. Rep. 2016, 6, 30696. [CrossRef]

71. Marzban, M.; Mousavizadeh, K.; Bakhshayesh, M.; Vousooghi, N.; Vakilzadeh, G.; Torkaman-Boutorabi, A. Effect of Multiple Intraperitoneal Injections of Human Bone Marrow Mesenchymal Stem Cells on Cuprizone Model of Multiple Sclerosis. Iran. Biomed. J. 2018, 22, 312–321. [CrossRef] [PubMed]

72. Singla, D.K.; Abdelli, L.S. Embryonic Stem Cells and Released Factors Stimulate c-kit(+)/FLK-1(+) Progenitor Cells and Promote Neovascularization in Doxorubicin-Induced Cardiomyopathy. Cell Transplant. 2015, 24, 1043–1052. [CrossRef] [PubMed]

73. Braun, R.K.; Chetty, C.; Balasubramaniam, V.; Centanni, R.; Haraldsdottir, K.; Hematti, P.; Eldridge, M.W. Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia. Biochem. Biophys. Res. Commun. 2018, 503, 2653–2658. [CrossRef] [PubMed]